Pfizer Considering Biotech Acquisitions; “Probably No” Big Mergers
Executive Summary
Pfizer is returning to acquisition mode, but with an eye on building its biotechnology presence rather than another major pharmaceutical merger
You may also be interested in...
UCB Acquiring Celltech; Phase III TNF Inhibitor At Center Of $2.7 Bil. Deal
UCB is paying $2.7 bil. to lock up rights to Celltech's TNF inhibitor CDP-870
UCB Acquiring Celltech; Phase III TNF Inhibitor At Center Of $2.7 Bil. Deal
UCB is paying $2.7 bil. to lock up rights to Celltech's TNF inhibitor CDP-870
Pfizer Recognizes “Dark Side” Of Scale In R&D; No Sales Force Cuts Planned
Pfizer relies on competition among research teams to help ensure that its vast R&D resources do not diminish the entrepreneurial spirit within the organization, CFO David Shedlarz told the Merrill Lynch pharmaceutical and biotechnology conference Feb. 5 in New York City